Centrexion To Present Data On CNTX-4975 For The Treatment Of Chronic Pain Associated With Morton’s Neuroma And Knee Osteoarthritis At American Pain Society 2017 Annual Scientific Meeting

BOSTON--(BUSINESS WIRE)--Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced it will present data from a Phase two clinical trial of CNTX-4975 for the treatment of Morton’s neuroma and from a pilot study on the safety and tolerability of CNTX-4975 in patients with chronic, moderate to severe knee pain associated with osteoarthritis at the American Pain Society’s (APS) 36th Annual Scientific Meeting taking place May 17 – 20, 2017 at the David L. Lawrence Convention Center in Pittsburgh.

Full abstracts are available online at http://americanpainsociety.org/. Details of the poster presentations are listed below.

Abstract Title (#384): CNTX-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects With Painful Intermetatarsal Neuroma (Morton’s Neuroma): A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Poster Discussion: 3:45-5:15 p.m. ET, Thursday, May 18
Location: Experience Exchange

Abstract Title (#382): Safety and Tolerability of CNTX-4975 in Subjects With Chronic, Moderate to Severe Knee Pain Associated With Osteoarthritis: A Pilot Study
Poster Discussion: 3:45-5:15 p.m. ET, Thursday, May 18
Location: Experience Exchange

About CNTX-4975

CNTX-4975 is based on Centrexion’s proprietary STRATI® technology (Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent, ultrapure, synthetic form of trans-capsaicin (a medicine traditionally derived from the chili plant). CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe pain without affecting touch sensibility or position sense.

CNTX-4975 works by selectively targeting the capsaicin receptor (TRPV1) to rapidly inactivate only the local pain fibers transmitting signals to the brain. With a short half-life, STRATI® is cleared from the body within 24 hours. This approach provides pain relief that can last for months until the ends of the local pain fibers regenerate, while maintaining normal sensation, such as touch, pressure and position, and without the risks of toxicities of NSAIDs and injected corticosteroids or the side effects, including abuse and addiction, associated with opioid treatments.

About Centrexion Therapeutics

Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.

For more information about Centrexion, visit http://www.centrexion.com.